Xcout IntelC2N Diagnostics, LLC
C2N Diagnostics, LLC is a biotechnology company that develops blood-based diagnostic tests for neurodegenerative diseases, particularly Alzheimer’s disease. Its Precivity d tests use mass spectrometry-based plasma biomarkers and are intended for use by healthcare providers and researchers in evaluating patients for Alzheimer’s pathology.
Subscribe to see C2N Diagnostics, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
C2N Diagnostics, LLC at a glance
C2N Diagnostics, LLC is a company headquartered in United States. Its most recent funding round, Debt, raised $20M in May 2026. Xcout tracks 10 named people at C2N Diagnostics, LLC, including Joel Braunstein (CEO).
C2N Diagnostics, LLC leadership
- Joel BraunsteinCEO
- Micah R. OnixtExecutive Vice President
- David HoltzmanScientific Co-Founder
- Randall BatemanScientific Co-Founder
- Dr. Joel BraunsteinExecutive Officer
- Micah OnixtExecutive Officer
4 more named people on record for C2N Diagnostics, LLC, with roles, board committees and tenure — see the full roster →
C2N Diagnostics, LLC funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Debt | $20M | 1 named | |
| SEC Form D filing | $10M | — | |
| Debt | $54M | 5 named | |
| SEC Form D filing | $25M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
C2N Diagnostics, LLC competitors
A few of C2N Diagnostics, LLC's closest competitors — see the full list of competitors and alternatives →
NeuroQuest Development Center, Inc. is a biotechnology company that operates a development center located in North Charleston, South Carolina, and announced plans to begin US clinical validation trials for an Alzheimer's blood test.
Veravas Inc. develops diagnostic technology and testing solutions, including its proprietary VeraBIND platform, designed to reduce laboratory test interference and detect hard-to-find biomarkers. The company primarily serves clinicians, researchers, and patients by providing tools and assays focused on the early detection of complex conditions such as Alzheimer's disease and other dementias.
Brazos Neuroscience is a neurodiagnostics company delivering objective, blood-based biomarker testing to support neurological assessment and research. Based in Texas, the company focuses on advancing neuroscience through clinical innovation.
i2Dx, Inc. is a US-based company founded in 2012 that develops a multimodal, cloud-based diagnostic platform. The platform is designed for the assessment and diagnosis of neurological disorders using quantitative digital assessments.
Cortexyme, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutics for major degenerative disorders.
Durin Life Sciences develops Duritect™, a blood-based test that combines autoantibody biomarkers with machine learning technology to assess patients' risk of having Alzheimer's disease or Parkinson's disease. The company provides laboratory analysis services to process these blood samples and deliver risk score reports to physicians and patients.
Get C2N Diagnostics, LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on C2N Diagnostics, LLC in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access